Cervical Cancer Claims Over 3.5 Lakh Lives Annually Globally: WHO

On the occasion of the first World Cervical Cancer Elimination Day, the World Health Organization (WHO) issued a sobering reminder: cervical cancer continues to claim more than 3.5 lakh lives each year worldwide, with a staggering 90% of deaths occurring in low- and middle-income countries. WHO emphasized that the disease is largely preventable, and thanks to effective tools like the HPV vaccine, elimination is no longer a dream but a global public health goal within reach.

A Global Call to Eliminate a Preventable Killer

WHO Director-General Dr. Tedros Adhanom Ghebreyesus noted,

• “What was once a distant dream is now becoming a reality. More countries are ramping up HPV vaccination and expanding access to screening and treatment.”

The announcement also highlighted Gavi, the Vaccine Alliance’s successful campaign, which reached its goal of protecting 86 million girls by the end of 2025 ahead of schedule. Gavi’s CEO, Dr. Sania Nishtar, stated,

• “Every two minutes, a woman dies from cervical cancer. But thanks to collaborative efforts, over one million lives have already been saved.”

Cervical Cancer in India: The Urgent Need for Action

In India, cervical cancer is the second most common cancer among women, with over 80,000 cases reported in 2023–24 alone. Despite its preventability, the HPV vaccine is yet to be included in the Universal Immunisation Programme (UIP), although it has been launched in Sikkim and Bihar on a limited scale.

The Union Budget 2024 earmarked a phased introduction of the vaccine, following recommendations from the National Technical Advisory Group on Immunisation (NTAGI) to vaccinate girls aged 9–14 years.

HPV Vaccine: A Lifesaving Shield Against Cervical Cancer

The HPV (Human Papillomavirus) vaccine offers up to 90% protection against cervical cancer, especially when administered before the onset of sexual activity. According to WHO, the vaccine prevents 17.4 deaths per 1,000 children vaccinated.

However, barriers such as low awareness, affordability, and infrastructure gaps continue to delay nationwide rollout in India, where screening and early detection remain limited, particularly in rural areas.

India’s Innovations: A ₹100 Test Kit and Growing Momentum

On the innovation front, doctors at AIIMS have developed a ₹100 cervical cancer detection kit capable of providing results in just two hours. This low-cost, rapid test is expected to revolutionize early screening, especially in underserved areas.

Such initiatives, coupled with awareness drives and public-private partnerships, are key to achieving WHO’s 90–70–90 targets,

• 90% of girls vaccinated with HPV vaccine
• 70% of women screened at least once
• 90% of women with cervical pre-cancer or cancer treated

Key Static Facts: Cervical Cancer & HPV Vaccine

• Annual Global Deaths (2022): Over 3,50,000
• Deaths in LMICs: 90% of global burden
• India Cases (2023–24): Over 80,000
• Vaccine Status in India: Limited rollout (Sikkim & Bihar); yet to be in UIP
• Recommended Age for Vaccination: 9–14 years (NTAGI)
• AIIMS Innovation: ₹100 cervical cancer test kit with 2-hour results.